The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Perinatal Guidelines Update
The "Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States" have been revised to include:
Updates to Clinical Scenario #3. The new information discusses a 3 to 7 day "tail" of postpartum maternal ZDV/3TC following single dose maternal/infant nevirapine; this "tail" may reduce the risk of nevirapine resistance.
Updated information on the role of cesarean delivery in preventing mother-to-child transmission of HIV.
An updated Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy, including a new section on tipranavir.
A Perinatal Antiretroviral Guidelines Working Group Conflict of Interest Disclosure (Appendix).
Updated information appears highlighted in yellow.
You can download the updated guidelines, or request to receive them by e-mail or hard copy from the AIDSinfo Web site: www.aidsinfo.nih.gov.
The AIDSinfo website is also a useful source of other information related to HIV/AIDS, including other treatment and prevention guidelines, downloadable databases for PDAs (Personal Digital Assistants), fact sheets, and HIV/AIDS-related clinical trials information.
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration